Siemens Healthineers AG
5-year stock timeline
Siemens Healthineers' last five years blend a COVID windfall, post-pandemic normalization, a substantial oncology bet through Varian, and a gradual return to its core identity as a steady MedTech compounder, with shares settling in the low-40s by early 2026.
2019–2020: Pre-COVID stability, then pandemic acceleration
The company arrived as a recently listed DAX MedTech player (IPO 2018) built on Imaging, Diagnostics, and Advanced Therapies—solid, high-quality, but fundamentally steady. The early pandemic period rewrote that script. Demand for diagnostic testing and imaging capacity spiked sharply, lifting revenues and margins. Rather than a cyclical risk, the market saw a resilient pandemic beneficiary, and the stock re-rated higher through 2020.
2020–2021: Varian and the platform narrative
Siemens Healthineers agreed to acquire Varian, a leading radiation oncology company, reshaping itself into a broader cancer-care platform. The deal brought leverage and integration complexity, but also promised a larger strategic moat. Investors embraced the story of a premium, innovation-driven compounder with a structurally bigger addressable market. Shares traded at elevated multiples on optimism about Varian synergies.
2021–2023: Post-COVID reality and China friction
COVID testing faded, and Diagnostics normalized while Imaging held steady. Cost inflation and Varian integration expenses created earnings pressure and guidance resets that weighed on the stock. Simultaneously, China's healthcare market shifted—pricing pressure, procurement changes—and became a persistent bear argument. The narrative tilted from pure growth to "a good business working through a hangover."
2023–2024: De-rating and defensive positioning
The company continued pushing Imaging and Advanced Therapies innovation while integrating Varian and generating stronger cash. Dividends held firm, reinforcing a defensive-compounder perception even as China remained a drag. The shares experienced a pronounced de-rating from prior highs, with year-over-year declines and extended ranges as the market discounted slower growth and regional risks. The company's scale, diversified segments, and strong balance sheet provided a valuation floor and set the stage for base-building.
2024–early 2026: Cash flow inflection and recalibrated expectations
Results showed mid-single-digit revenue growth, particularly strong in Imaging and Varian, alongside materially stronger free cash flow. Management reaffirmed guidance and raised the dividend (to €1.00 per share, up €0.05), signaling confidence despite China and tariff headwinds. The emerging view frames Siemens Healthineers as an innovation-led, cash-generative MedTech with genuine upside from imaging and cancer care, tempered by China exposure. Investors increasingly see a quality, moderately undervalued healthcare name rather than a high-flyer—trading below internal fair-value estimates and showing a longer-term sideways-to-up pattern after earlier drawdowns.
Key risks and downside factors
Siemens Healthineers AG (SHL.XETRA) holds a strong position in medical imaging, in-vitro diagnostics, and advanced therapies within a tightly controlled market dominated by a handful of major players.[16][page:2] GE HealthCare and Philips stand as the primary competitors, each commanding broad diagnostic imaging and healthcare technology portfolios backed by comparable scale and R&D firepower.[page:2][21] The competitive landscape is tightening as established rivals and lower-cost manufacturers from Asia intensify pricing and innovation across imaging, lab diagnostics, and digital health.[16][page:2] This creates a particular set of pressures for the company: sustained pricing headwinds, the relentless capital demands of R&D, and the cyclical nature of hospital spending and regulatory shifts.[16][6]
- Intense competition from large diversified medtech peers like GE HealthCare, Philips, Canon, and Fujifilm in diagnostic imaging, in-vitro diagnostics, and advanced therapies constrains pricing power and puts margin pressure on the company.[page:2][16]
- Aggressive pricing from lower-cost Asian manufacturers and AI-native software competitors in imaging and diagnostics poses a real threat to market share, particularly in cost-sensitive emerging markets and tender processes.
- The company needs to invest billions of euros annually in research, development, and capital expenditure to stay competitive in imaging hardware, diagnostics, and AI software. If product launches disappoint or reimbursement rates lag behind these investments, execution risk rises materially.[16][page:2]
- The company faces meaningful exposure to healthcare regulations, product approvals, and quality standards across its global operations. Hospital capital-spending cycles add another layer—delays in approvals, compliance challenges, or tightening budgets can all meaningfully impact equipment orders and service revenues.
Competitive landscape
SHL Telemedicine Ltd. (SHL.XETRA / SHLTN.SW) operates as a niche telemedicine and B2B healthcare services provider, with its main footprint in Israel, a struggling telemedicine platform in Germany, and an emerging cardiology business in the U.S. The competitive landscape includes larger listed telehealth and virtual-care networks alongside regional managed-care and digital-health platforms focused on chronic-care monitoring and remote diagnostics. Competition runs deep, especially in Germany and the U.S., where SHL faces well-capitalized, faster-growing competitors while navigating restructuring efforts and goodwill impairments. The company carries elevated risk from ongoing losses, significant intangible asset write-downs, heavy reliance on its Israeli operations, and looming refinancing and minority-buyout obligations.
| Company | Ticker |
|---|---|
| Teladoc Health Inc. | TDOC.NYSE |
| Doximity Inc. | DOCS.NYSE |
| The Cigna Group | CI.NYSE |
| American Well Corporation (Amwell) | AMWL.NYSE |
| LifeMD Inc. | LFMD.NASDAQ |
Private competitors
- DOCGO Inc. (operating partner / virtual care provider)
- German chronic‑care and telemonitoring networks contracted with statutory health insurers
- Regional Israeli telemedicine and diagnostic‑clinic chains competing with SHL Israel and Mediton
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialPerformance Figures of Siemens Healthineers AG
Relative Performance vs Benchmarks
| Period | Siemens Healthineers AG | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | +0.46% | +0.06% | +1.27% |
| 3M | -0.72% | -4.63% | -1.73% |
| 6M | -9.21% | -13.63% | -16.45% |
| 1Y | -21.20% | -30.45% | -38.08% |
| 3Y | -13.08% | -71.23% | -89.74% |
| 5Y | +0.70% | -74.29% | -92.08% |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHistorical valuation trends
How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 21.9 | 2.0 | 2.5 | 17.8 |
| 1Y ago | 30.6 | 2.7 | 3.1 | 19.6 |
| 3Y ago | 27.5 | 2.5 | 3.0 | 33.3 |
| 5Y ago | 32.0 | 3.3 | 4.0 | 21.8 |
Key Metrics
Valuation Metrics
Profitability Metrics
Growth Metrics
Dividend history
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 1.00 EUR | 2.35% | 1.85% |
| 2025 | 0.95 EUR | 1.66% | |
| 2024 | 0.95 EUR | 1.86% | |
| 2023 | 0.95 EUR | 1.85% | |
| 2022 | 0.85 EUR | 1.52% | |
| 2021 | 0.80 EUR | 1.64% | |
| 2020 | 0.80 EUR | 1.94% | |
| 2019 | 0.70 EUR | 1.98% |
Earnings history & estimates
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Historical earnings performance
Upcoming earnings report
Analyst estimates for upcoming periods
Key financial figures
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 23.38B | 22.36B | 21.68B | 21.71B | 18.00B |
| Operating income (EBIT) | 3.44B | 3.30B | 2.44B | 3.06B | 2.78B |
| Net income | 2.14B | 1.94B | 1.51B | 2.04B | 1.73B |
| Free cash flow | 2.27B | 1.77B | 1.28B | 1.65B | 2.26B |
| Total assets | 44.37B | 46.05B | 46.68B | 49.06B | 41.93B |
| Equity | 18.04B | 18.20B | 18.08B | 19.84B | 16.04B |
| Net debt | 12.89B | 13.53B | -1.01B | -704.00M | 12.99B |
PWP Leeway UG (haftungsbeschränkt)
